Literature DB >> 28932874

[Epilepsy-new diagnostic tools, old drugs? : Therapeutic consequences of epilepsy genetics].

M Tacke1, B A Neubauer2, L Gerstl1, T Roser1, J Rémi3,4, I Borggraefe5,6.   

Abstract

BACKGROUND: Recent advances in the field of epilepsy genetics have led to an increased fraction of patients with epilepsies where the etiology of the disease could be identified. Nevertheless, there is some criticism regarding the use of epilepsy genetics because in many cases the identification of a pathogenetic mutation does not lead to an adaptation of therapy or to an improved prognosis. In addition, the interpretation of genetic results might be complicated due to the considerable numbers of variants of unclear significance.
OBJECTIVE: This publication presents the arguments in favour of a broad use of genetic investigations for children with epilepsies. Several diseases where a genetic diagnosis does in fact have direct therapeutic consequences are mentioned. In addition, the indirect impact of an established etiology, encompassing the avoidance of unnecessary diagnostic measures, possibility of genetic counselling, and the easing of the psychologic burden for the caregivers, should not be underestimated.
CONCLUSION: The arguments in favour of broad genetic diagnostics prevail notwithstanding the lack of relevant new developments regarding the therapy.

Entities:  

Keywords:  Drugs; Epilepsy; Epilepsy surgery; Genetics; Prognosis

Mesh:

Substances:

Year:  2017        PMID: 28932874     DOI: 10.1007/s00115-017-0427-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  33 in total

Review 1.  Cerebrospinal fluid analysis in the workup of GLUT1 deficiency syndrome: a systematic review.

Authors:  Wilhelmina G Leen; Ron A Wevers; Erik-Jan Kamsteeg; Hans Scheffer; Marcel M Verbeek; Michèl A Willemsen
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

2.  Genetic testing preferences in families containing multiple individuals with epilepsy.

Authors:  Janice O Okeke; Virginia E Tangel; Shawn T Sorge; Dale C Hesdorffer; Melodie R Winawer; Jeff Goldsmith; Jo C Phelan; Wendy K Chung; Sara Shostak; Ruth Ottman
Journal:  Epilepsia       Date:  2014-09-29       Impact factor: 5.864

3.  Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders.

Authors:  Markus Wolff; Katrine M Johannesen; Ulrike B S Hedrich; Silvia Masnada; Guido Rubboli; Elena Gardella; Gaetan Lesca; Dorothée Ville; Mathieu Milh; Laurent Villard; Alexandra Afenjar; Sandra Chantot-Bastaraud; Cyril Mignot; Caroline Lardennois; Caroline Nava; Niklas Schwarz; Marion Gérard; Laurence Perrin; Diane Doummar; Stéphane Auvin; Maria J Miranda; Maja Hempel; Eva Brilstra; Nine Knoers; Nienke Verbeek; Marjan van Kempen; Kees P Braun; Grazia Mancini; Saskia Biskup; Konstanze Hörtnagel; Miriam Döcker; Thomas Bast; Tobias Loddenkemper; Lily Wong-Kisiel; Friedrich M Baumeister; Walid Fazeli; Pasquale Striano; Robertino Dilena; Elena Fontana; Federico Zara; Gerhard Kurlemann; Joerg Klepper; Jess G Thoene; Daniel H Arndt; Nicolas Deconinck; Thomas Schmitt-Mechelke; Oliver Maier; Hiltrud Muhle; Beverly Wical; Claudio Finetti; Reinhard Brückner; Joachim Pietz; Günther Golla; Dinesh Jillella; Karen M Linnet; Perrine Charles; Ute Moog; Eve Õiglane-Shlik; John F Mantovani; Kristen Park; Marie Deprez; Damien Lederer; Sandrine Mary; Emmanuel Scalais; Laila Selim; Rudy Van Coster; Lieven Lagae; Marina Nikanorova; Helle Hjalgrim; G Christoph Korenke; Marina Trivisano; Nicola Specchio; Berten Ceulemans; Thomas Dorn; Katherine L Helbig; Katia Hardies; Hannah Stamberger; Peter de Jonghe; Sarah Weckhuysen; Johannes R Lemke; Ingeborg Krägeloh-Mann; Ingo Helbig; Gerhard Kluger; Holger Lerche; Rikke S Møller
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

4.  Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex.

Authors:  Sergiusz Jóźwiak; Katarzyna Kotulska; Dorota Domańska-Pakieła; Barbara Lojszczyk; Małgorzata Syczewska; Dariusz Chmielewski; Dorota Dunin-Wąsowicz; Tomasz Kmieć; Joanna Szymkiewicz-Dangel; Maria Kornacka; Wanda Kawalec; Dariusz Kuczyński; Julita Borkowska; Katarzyna Tomaszek; Elżbieta Jurkiewicz; Maria Respondek-Liberska
Journal:  Eur J Paediatr Neurol       Date:  2011-04-19       Impact factor: 3.140

5.  Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.

Authors:  C Chiron; M C Marchand; A Tran; E Rey; P d'Athis; J Vincent; O Dulac; G Pons
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

Review 6.  Combining antiepileptic drugs--rational polytherapy?

Authors:  Martin J Brodie; Graeme J Sills
Journal:  Seizure       Date:  2011-02-08       Impact factor: 3.184

7.  Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

Authors:  David Neal Franz; Elena Belousova; Steven Sparagana; E Martina Bebin; Michael Frost; Rachel Kuperman; Olaf Witt; Michael H Kohrman; J Robert Flamini; Joyce Y Wu; Paolo Curatolo; Petrus J de Vries; Vicky H Whittemore; Elizabeth A Thiele; James P Ford; Gaurav Shah; Helene Cauwel; David Lebwohl; Tarek Sahmoud; Sergiusz Jozwiak
Journal:  Lancet       Date:  2012-11-14       Impact factor: 79.321

8.  A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  O K Steinlein; J C Mulley; P Propping; R H Wallace; H A Phillips; G R Sutherland; I E Scheffer; S F Berkovic
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

9.  Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.

Authors:  Jacqueline A French; John A Lawson; Zuhal Yapici; Hiroko Ikeda; Tilman Polster; Rima Nabbout; Paolo Curatolo; Petrus J de Vries; Dennis J Dlugos; Noah Berkowitz; Maurizio Voi; Severine Peyrard; Diana Pelov; David N Franz
Journal:  Lancet       Date:  2016-09-06       Impact factor: 79.321

10.  PRRT2 Is a Key Component of the Ca(2+)-Dependent Neurotransmitter Release Machinery.

Authors:  Pierluigi Valente; Enrico Castroflorio; Pia Rossi; Manuela Fadda; Bruno Sterlini; Romina Ines Cervigni; Cosimo Prestigio; Silvia Giovedì; Franco Onofri; Elisa Mura; Fabrizia C Guarnieri; Antonella Marte; Marta Orlando; Federico Zara; Anna Fassio; Flavia Valtorta; Pietro Baldelli; Anna Corradi; Fabio Benfenati
Journal:  Cell Rep       Date:  2016-03-24       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.